OB/GYN 1109 - OB/GYN Clinical Alert - Sep 01, 2007

Target Audience:

This activity is intended for the obstetrician and gynecologist.


AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Leon Speroff, MD
Professor of Obstetrics and Gynecology
Oregon Health and Science University

Peer Reviewer
Catherine Leclair, MD
Assistant Professor
Department of OB/GYN
Oregon Health and Science University

Associate Editors
Robert L. Coleman, MD
Associate Professor
University of Texas
M.D. Anderson Cancer Center

John C Hobbins, MD
Professor and Chief of Obstetrics
University of Colorado Health Sciences Center

Eileen C. West, MD
Director of Primary Care
Women's Health
Clinical Assistant Professor of Internal Medicine
University of Oklahoma School of Medicine
Oklahoma City


  • SSRIs and Fractures
  • Gemcitabine vs Pegylated Liposomal Doxorubicin in Patients with Platinum-resistant Ovarian Cancer
  • Neonatal and Five Year Outcomes after Birth at 30-34 Weeks of Gestation
  • Change in Breast Cancer Prevalence
  • Dietary Intake and Prognosis after Breast Cancer


  • To present the latest data regarding diagnosis and treatment of various diseases affecting women, including cancer, sexually transmitted diseases, and osteoporosis
  • To present new data concerning prenatal care and complications, as well as neonatal health
  • To discuss the pros, cons, and cost-effectiveness of new testing procedures

Financial Disclosure:

OB/GYN Clinical Alert’s Editor, Leon Speroff, MD, is a consultant for Warner-Chilcott. Peer Reviewer Catherine Leclair, MD, Associate Editors Robert L. Coleman, MD, John C. Hobbins, MD, and Author Eileen C. West, MD, reports no financial relationship to this field of study.

Copyright 2007 AHC Media. All rights reserved.